1.
Eur J Anaesthesiol
; 38(4): 438-441, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1116604
Asunto(s)
Anestesia/efectos adversos , Anestésicos por Inhalación/efectos adversos , COVID-19 , Diabetes Insípida Nefrogénica/inducido químicamente , Hipnóticos y Sedantes/efectos adversos , SARS-CoV-2 , Sevoflurano/efectos adversos , Anestésicos por Inhalación/administración & dosificación , Humanos , Hipnóticos y Sedantes/administración & dosificación , Sevoflurano/administración & dosificación
2.
Intensive Care Med
; 46(8): 1563-1566, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: covidwho-614084
RESUMEN
Hospitals worldwide are experiencing a shortage in essential intravenous sedative medications. This is attributable to high number and high sedative needs of COVID-19 critical care patients with disruption of drug supply chains. Inhaled volatile anesthetic agents are an abundant resource and readily implementable solution for providing ICU sedation. Inhaled volatile agents may also provide important pulmonary benefits for COVID-19 patients with ARDS that could improve gas exchange and reduce time spent on a ventilator. We review the use of volatile agents, and provide a technical overview and algorithm for administering inhaled volatile-based sedation in ICUs.